What is Seaport Therapeutics 's non-cash interest expense?

Seaport Therapeutics (SPTX) reported non-cash interest expense of -$223K in Q1 2026.

Seaport Therapeutics SPTX Non-cash interest expense

Non-cash interest expense at other companies

Laureate Education, Inc.LAUR

$593K+56.1%

Navan, Inc. NAVN

$447K-95.5%

Rhythm Pharmaceuticals, Inc.RYTM

$4.58M-15.4%

TransDigm GroupTDG

$12M+20.0%

Flutter EntertainmentFLUT

$67M+458%

O'Reilly AutomotiveORLY

$1.89M+1.9%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's non-cash interest expense?: Seaport Therapeutics (SPTX) reported non-cash interest expense of -$223K in Q1 2026.